Celltrion
Celltrion is a South Korea-based pharmaceutical company running 2 late-stage cancer trials of CT-P51 and CT-P44(Daratumumab) in non-small-cell lung cancer and multiple myeloma.
Overview
Celltrion, based in Incheon, South Korea, is a pharmaceutical company listed as KRX: 068270. Celltrion is a biopharmaceutical company that researches, develops, manufactures and markets biosimilars and novel therapeutics across immunology, oncology and ophthalmology. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3), testing CT-P51 and CT-P44(Daratumumab) in non-small-cell lung cancer and multiple myeloma. The largest, NCT06952478 (A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma), plans to enrol 486 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry, checked on 2026-09-11; company facts are from the official website.
Similar pages
not linked directly; found by shared links- CompanyChongqing Precision Biotech
Shares Multiple myeloma and the tag ctgov-sponsor.
- CompanyAvistone Biotechnology
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyMaia Biotechnology
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyShanghai AbelZeta
Shares Multiple myeloma and the tag ctgov-sponsor.
- CompanyNanjing Leads Biolabs
Shares Multiple myeloma, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanySTCube
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyCivaTech Oncology
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyKrystal Biotech
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.